Seaport Therapeutics Reports Positive Phase 1 GlyphAllo Data
BOSTON — September 9, 2026 Seaport Therapeutics, Inc. reported positive topline results from a Phase 1 driving simulation trial...
oral therapy
Advertisement
Prelude Therapeutics Gains FDA Clearance for PRT13722
WILMINGTON, Del. — September 10, 2026 Prelude Therapeutics Incorporated announced that the U.S. Food and Drug Administration (FDA) has...
Seaport Therapeutics Advances GlyphAllo in Major Depression
BOSTON — September 9, 2026 Seaport Therapeutics, Inc. announced positive topline results from a Phase 1 driving simulation trial...
Beeline Medicines Advances Afimetoran Toward Pivotal Lupus Trials
STAMFORD, Conn. — September 9, 2026 Beeline Medicines Corporation announced positive topline results from its global Phase 2 study...
Pharvaris Reports Positive Phase 3 CHAPTER-3 Data for Deucrictibant XR
ZUG, Switzerland — September 8, 2026 Pharvaris announced positive topline results from the CHAPTER-3 pivotal Phase 3 study evaluating...
Advertisements
Masimo Gains CE Mark for AI-Powered Brain Monitor
Irvine, California, August 18, 2026 Masimo has received the CE Mark for its next-generation smartSedLine™ brain function monitor, introducing...
BioMarin to Acquire Alesta for Potential Oral HPP Treatments
SAN RAFAEL, Calif., August 18, 2026 BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Alesta Therapeutics,...
Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
Sagimet Biosciences Secures FDA Clearance for Acne Phase 3 Trial
FOSTER CITY, Calif., August 13, 2026 Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Evommune Launches Phase 2b Trial of EVO756 for Migraine Prevention
PALO ALTO, Calif., & NEW YORK, July 30, 2026 Evommune announced that the first patient has been dosed in...
Advertisement
